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Summary  The  autonomic  nervous  system  (ANS)  conveys  neuronal  input  from  the  brain  to
the stomach.  We  investigated  mechanisms  through  which  urocortin  1  (UCN1)  injected  intrac-
erebroventricularly  (ICV,  300  pmol/rat)  inhibits  circulating  ghrelin  in  rats.  This  was  achieved
by assessing  (1)  the  induction  of  c-fos  gene  expression  as  a  marker  of  neuronal  activation  in
speciﬁc hypothalamic  and  caudal  brainstem  regulating  ANS;  (2)  the  inﬂuence  of  vagotomy  and
pharmacological  blockade  of  central  and  peripheral  -  and  -adrenergic  receptor  (AR)  on  ICV
UCN1-induced  reduction  of  plasma  ghrelin  levels  (determined  by  ELISA);  and  (3)  the  relevance
of this  pathway  in  the  feeding  response  to  a  fast  in  rats.  UCN1  increased  c-fos  mRNA  expres-
sion in  key  brain  sites  inﬂuencing  sympathetic  activity  namely  the  hypothalamic  paraventricular
and ventromedial  nuclei,  locus  coeruleus,  nucleus  of  the  solitary  tract,  and  rostral  ventrolateral
medulla, by  16-,  29-,  6-,  37-,  and  13-fold,  respectively.  In  contrast,  the  dorsal  motor  nucleus
of the  vagus  had  little  c-fos  mRNA  expression  and  ICV  UCN1  induced  a  similar  reduction  in
acylated ghrelin  in  the  sham-operated  (31%)  and  vagotomized  (41%)  rats.  An  intraperitoneal
(IP) injection  of  either  a  non-selective  -  or  selective  2-AR  antagonist  reduced,  while  a
selective 2-AR  agonist  enhanced  ICV  UCN1-induced  suppression  of  plasma  acylated  ghrelin
levels. In  addition,  IP  injection  of  a  non-selective  -  or  selective  1-AR  agonist  blocked,  and
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selective  1-AR  antagonist  augmented,  the  ghrelin  response  to  ICV  UCN1.  The  IP  injections  of  a
selective 1-  or  non-selective    or  2-AR  antagonists,  or  any  of  the  pretreatments  given  ICV  had
no effect.  ICV  UCN1  reduced  the  2-h  food  intake  in  response  to  a  fast  by  80%,  and  this  effect  was
partially prevented  by  a  selective  2-AR  antagonist.  These  data  suggest  that  ICV  UCN1  reduces
plasma ghrelin  mainly  through  the  brain  sympathetic  component  of  the  ANS  and  peripheral  AR
speciﬁcally  2-AR  activation  and  inactivation  of  1-AR.  The  2-AR  pathway  contributes  to  the
associated reduction  in  food  intake.
© 2014  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under  the  CC
ative
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Eight-week-old  male  Sprague-Dawley  rats  (weight,
240—280  g)  were  purchased  from  Japan  SLC,  Inc.  (Shizuoka,BY-NC-ND  license  (http://cre
1. Introduction
Stress  is  well  established  to  inﬂuence  feeding  behaviors
and  metabolism  in  both  humans  and  rodents  (Patterson  and
Abizaid,  2013).  Corticotropin-releasing  factor  (CRF)  plays  a
key  role  in  coordinating  the  hormonal,  autonomic,  behav-
ioral  and  visceral  components  of  the  acute  stress  response
(Stengel  et  al.,  2010a).  In  rodents,  CRF  administered  into
the  brain  induces  stress-like  behaviors,  including  increased
anxiety-like  manifestations  and  food  intake  suppression
(Stengel  and  Taché,  2014;  Zorrilla  et  al.,  2003).  Urocortin  1
(UCN1)  is  a  member  of  the  mammalian  CRF-related  peptide
that  is  mainly  localized  in  the  Edinger—Westphal  nucleus,
and  to  a  lesser  extent,  in  the  olfactory  bulb,  supraop-
tic  nucleus,  ventromedial  hypothalamus  (VMH)  and  lateral
hypothalamic  area  (Kozicz  et  al.,  1998;  Shah  et  al.,  2013).
Evidence  suggests  that  experimental  stressors  activate  UCN1
neurons  in  the  Edinger-Westphal  nucleus  (Gaszner  et  al.,
2004).  Both  CRF  and  UCN1  mediate  their  actions  through  the
activation  of  CRF  receptor  subtypes  1  and  2  (CRF1 and  CRF2,
respectively);  however,  CRF  and  UCN1  exhibit  differential
binding  afﬁnities.  UCN1  displays  high  afﬁnity  to  both  CRF
receptor  subtypes,  while  CRF  is  a  preferential  CRF1 agonist
and  has  a  low  afﬁnity  to  CRF2 (Vaughan  et  al.,  1995).
It  is  well  documented  that  UCN1  injected  intracere-
broventricularly  (ICV)  is  more  potent  than  CRF  to  suppress
fasting-  or  dark  phase-induced  food  intake  without  induc-
ing  conditioned  taste  aversion  or  visceral  illness  in  rodents
(Benoit  et  al.,  2000;  Smagin  et  al.,  1998;  Spina  et  al.,  1996).
ICV  UCN1-induced  food  intake  inhibition  action  is  medi-
ated  mainly  through  the  activation  of  brain  CRF2 in  rats
(Smagin  et  al.,  1998;  Yakabi  et  al.,  2011).  Several  brain  sites
expressing  high  density  of  CRF2 (Bittencourt  et  al.,  1999)
and  regulate  the  autonomic  nervous  system  (ANS)  (Saper,
2002)  have  been  identiﬁed  to  be  responsive  to  UCN1,  which
results  in  a  CRF2-mediated  anorexigenic  response  in  rats,
namely  the  lateral  septum  (Bakshi  et  al.,  2007),  paraven-
tricular  nucleus  of  the  hypothalamus  (PVN)  (Currie  et  al.,
2001),  VMH  (Chen  et  al.,  2012;  Ohata  et  al.,  2000),  and  dor-
sal  raphe  (Weitemier  and  Ryabinin,  2006).  In  addition,  based
on  the  observation  that  UCN1  injected  into  the  fourth  brain
ventricle  is  still  able  to  reduce  food  intake  in  chronically
decerebrated  rats  (Daniels  et  al.,  2004),  hindbrain  struc-
tures  are  believed  to  be  involved  in  this  response.  This  is
consistent  with  the  earlier  report  that  the  nucleus  tractus
solitarius  (NTS)  is  a  brainstem  site  that  is  responsive  to  UCN1
(Grill  et  al.,  2000).
Several  potential  mechanisms  could  participate  in  the
anorexic  effects  of  ICV  UCN1.  The  ICV  injection  of  UCN1
induces  a  CRF2-mediated  inhibition  of  gastric  emptying
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(commons.org/licenses/by-nc-nd/3.0/).
Martinez  et  al.,  2004;  Yakabi  et  al.,  2011) and  hyper-
lycemia  (Grill  et  al.,  2000) in  rodents.  Both  effects  are
nown  to  reduce  feeding  (Cha  et  al.,  2008;  Phillips  and
owley,  1996).  In  addition,  we  have  recently  reported  that
CN1  ICV  acts  through  the  CRF2 receptor  to  decrease  circu-
ating  acylated  ghrelin  (Yakabi  et  al.,  2011),  which  is  the  only
nown  orexigenic  hormone  that  is  produced  peripherally  by
astric  endocrine  X/A  cells  but  acts  centrally  (Hosoda  et  al.,
002;  Muller  and  Tschop,  2013).  Of  functional  relevance,  we
ave  shown  that  the  exogenous  injection  of  ghrelin  or  the
hrelin  enhancer  rikkunshito  (Takeda  et  al.,  2012) restored
ood  intake  in  ICV  UCN1-injected  rats  (Yakabi  et  al.,  2011).
owever,  the  mechanism(s)  through  which  the  circulating
hrelin  is  suppressed  by  the  central  administration  of  UCN1
s  yet  to  be  elucidated.  Changes  in  the  ANS  activity  inﬂuence
astric  ghrelin  secretion  (Hosoda  and  Kangawa,  2008),  and
arious  local  classical  neurotransmitters  and  neuropeptides
re  reportedly  to  inﬂuence  ghrelin  release  (de  la  Cour  et  al.,
007;  Stengel  et  al.,  2011).  Previous  reports  indicate  that
entrally  injected  UCN1  effects  on  gastric  function  involve
he  ANS  (Czimmer  et  al.,  2006;  De  Fanti  and  Martinez,  2002).
In  the  present  study,  we  ﬁrst  delineated  the  ANS  path-
ay(s)  that  contributes  to  the  decreased  circulating  ghrelin
nduced  by  ICV  injection  of  UCN1  in  rats.  This  was  achieved
y  surgical  approach  (vagotomy)  and  mapping  the  induction
f  c-fos  gene  expression  as  a  marker  of  neuronal  activation
Krukoff,  1993),  in  speciﬁc  hypothalamic  (PVN,  VMH)  and
rainstem  [LC  (locus  coeruleus),  NTS,  DMN  (dorsal  motor
ucleus),  RVLM  (rostral  ventrolateral  medulla)]  nuclei  that
egulate  the  ANS  (Saper,  2002;  Toth  et  al.,  1999;  Travagli
t  al.,  2006).  Then,  we  assessed  the  related  peripheral
drenergic  mechanisms  using  the  pharmacological  blockade
f  central  and  peripheral  - and  -adrenergic  receptors
ARs).  Lastly,  we  examined  the  functional  implications  of
hrelin  suppression  in  the  inhibition  of  food  intake  induced
y  ICV  UCN1  using  blockade  of  identiﬁed  AR  pathways  alone
r  in  combination  with  a ghrelin  receptor  antagonist  or  the
hrelin  enhancer,  rikkunshito  (Takeda  et  al.,  2012).
.  Materials and methods
.1.  Animalsapan).  All  animals  were  housed  in  polycarbonate  cages
n  room  with  controlled  conditions  of  ambient  tem-
erature  (23  ±  3 ◦C),  humidity  (50  ±  20%),  and  lighting
12-h  light:dark  cycle  starting  at  7:00  PM).  Animals  were
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aintained  with  water  and  standard  laboratory  food  ad  libi-
um.  Access  to  the  standard  laboratory  food  was  removed
6  h  before  experiments,  which  were  conducted  between
 and  5  h  after  the  beginning  of  the  light  cycle  to  avoid  the
nﬂuences  of  diurnal  rhythms.  All  experimental  procedures
ere  performed  according  to  the  Guidelines  for  the  Care  and
se  of  Laboratory  Animals  and  approved  by  the  Laboratory
nimal  Committee  of  Tsumura  &  Co.  (Tokyo,  Japan).
.2.  Surgery
.2.1.  Intracerebroventricular  cannula
ats  under  sodium  pentobarbital  (50  mg/kg,  intraperitoneal,
P)  anesthesia  were  placed  on  a  stereotaxic  apparatus
Japan  SLC  Inc.,  Shizuoka,  Japan).  A  stainless  steel  guide
annula  (AG-8;  Eicom,  Kyoto,  Japan)  was  implanted  into
he  right  lateral  ventricle  using  the  following  coordinates
erived  from  the  rat  brain  atlas  (Paxinos  and  Watson,  1998):
.8  mm  posterior  and  1.4  mm  lateral  from  the  bregma  and
.4  mm  ventral  from  the  skull  surface.  Rats  were  singly
oused  after  the  surgery  and  had  at  least  a  recovery  period
f  5  days  before  the  start  of  the  treatment.
.2.2.  Subdiaphragmatic  vagotomy
he  surgery  was  performed  at  least  10  days  after  ICV  can-
ulation  as  previously  described  (Hosoda  and  Kangawa,
008;  Takeda  et  al.,  2008)  in  pentobarbital-anesthetized  rats
40  mg/kg,  IP).  Following  a  laparotomy,  both  vagal  trunks
ocated  at  the  lower  esophagus  were  resected,  and  a  pyloro-
lasty  was  performed  to  widen  the  pylorus  and  prevent
yloric  stenosis.  Sham  operations  consisted  of  the  opening
f  the  abdomen  and  exposure  of  the  internal  organs.  The
bdomen  was  closed  by  sutures.  Animals  had  at  least  6  days
f  recovery  time  and  maintained  under  standard  ad  libitum
ood.
.3.  Drugs  and  treatments
at  UCN1  was  purchased  from  Peptide  Institute,  Inc.
Osaka,  Japan).  Phentolamine  hydrochloride  (non-selective
-AR  antagonist),  prazosin  hydrochloride  (selective  1-
R  antagonist),  yohimbine  hydrochloride  (selective  2-AR
ntagonist),  propranolol  (non-selective  -AR  antagonist),
tenolol  (selective  1-AR  antagonist),  ICI-118,551  (selec-
ive  2-AR  antagonist),  synephrine  (non-selective  -AR
gonist),  phenylephrine  hydrochloride  (selective  1-AR  ago-
ist),  clonidine  hydrochloride  (selective  2-AR  agonist),
soproterenol  hydrochloride  (non-selective  -AR  agonist),
enopamine  (selective  1-AR  agonist),  and  salbutamol
selective  2-AR  agonist)  were  all  purchased  from  Sigma-
ldrich  Chemical  Co.  (St.  Louis,  MO,  USA).  The  growth
ormone  secretagogue  receptor  type  1a  (GHS-R1a)  antag-
nist,  [D-Lys3]-GHRP-6,  was  purchased  from  Bachem,  Inc.
Torrance,  CA,  USA).  These  compounds  were  dissolved  in
aline  when  injected  IP  and  in  phosphate-buffered  saline
PBS)  when  injected  ICV.  Rikkunshito,  which  is  a  Japanese
ampo  medicine,  was  supplied  from  Tsumura  &  Co.  (Tokyo,
apan)  in  the  form  of  a  powdered  extract  obtained  by
pray-drying  a  hot  water  extract  mixture  of  the  follow-
ng  eight  crude  drugs:  Atractylodis  lanceae  rhizoma  (4.0  g),
inseng  radix  (4.0  g),  Pinelliae  tuber  (4.0  g),  Poria  (4.0  g),
L
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izyphi  fructus  (2.0  g),  Aurantii  nobilis  pericarpium  (2.0  g),
lycyrrhizae  radix  (1.0  g),  and  Zingiberis  rhizoma  (0.5  g).
ikkunshito  was  dissolved  in  distilled  water  for  oral  admin-
stration.  Components  of  rikkunshito  for  binding  assay  were
issolved  in  dimethyl  sulfoxide  (DMSO,  ﬁnal  dilution:  1%).
ther  analytical  reagents  were  highest-purity  commercially
vailable  products.
Treatments  were  performed  on  lightly  hand-restrained
ats  in  the  following  volumes:  10  L/rat  for  ICV  injection,
 mL/kg  for  IP  or  intravenous  (IV)  injection  through  tail  vein,
nd  10  mL/kg  for  orogastric  administration.  Rats  were  han-
led  daily  more  than  5  days  prior  to  treatment  to  minimize
tress  during  the  procedure.
.4.  Ghrelin  determination
ats  were  euthanized  by  decapitation,  and  trunk  blood
approximately  4  mL)  was  collected  in  cold  polypropyl-
ne  tubes  containing  8.0  mg  ethylenediaminetetraacetic
cid  and  0.8  mg  aprotinin.  Samples  were  centrifuged  at
0,000  ×  g  at  4 ◦C  for  3  min.  The  supernatant  was  acid-
ﬁed  with  1  M  HCl  (1/10  volume)  and  stored  at  −80 ◦C
ntil  the  ghrelin  assays  were  performed.  Plasma  ghrelin
evels  were  determined  using  active  ghrelin  and  des-
cyl  ghrelin  Enzyme-Linked  Immunoassay  Kits  (Mitsubishi
hemical  Corp.,  Tokyo,  Japan).  The  detection  limits  for
he  acylated  and  des-acyl  ghrelin  were  2.7  fmol/mL  and
2.3  fmol/mL,  respectively.  The  intraassay  coefﬁcients  of
ariation  for  the  acylated  and  des-acyl  ghrelin  were
.8—4.8%  and  2.2—5.5%,  respectively,  and  the  interassay
oefﬁcients  of  variation  for  the  acylated  ghrelin  and  des-acyl
hrelin  were  2.8—6.4%  and  1.9—9.0%,  respectively.
.5.  Binding  afﬁnity  of  rikkunshito  for  ARs
or  the  2A-AR  binding  assay,  insect  Sf9  cells  expressing
uman  recombinant  2A-AR  were  homogenized  in  modiﬁed
ris—HCl  buffer  and  aliquots  were  incubated  with  1  nM  [3H]
K-912  for  60  min  at  25 ◦C.  Nonspeciﬁc  binding  was  esti-
ated  in  the  presence  of  10  M  WB-4101  (Uhlen  et  al.,
994).  For  2B-AR,  CHO-K1  cells  stably  transfected  with  a
lasmid  encoding  human  2B-AR  were  homogenized  in  mod-
ﬁed  Tris—HCl  buffer  using  standard  techniques  and  aliquots
ere  incubated  with  2.5  nM  [3H]  rauwolscine  for  60  min
t  25 ◦C.  Nonspeciﬁc  binding  was  estimated  in  the  pres-
nce  of  10  M  prazosin  (Uhlen  et  al.,  1998).  For  2C-AR,
nsect  Sf9  cells  expressing  human  recombinant  2C-AR  were
omogenized  in  modiﬁed  Tris—HCl  buffer  and  aliquot  was
ncubated  with  1  nM  [3H]  MK-912  for  60  min  at  25 ◦C.  Non-
peciﬁc  binding  was  estimated  in  the  presence  of  10  M
B-4101  (Uhlen  et  al.,  1994).  Radio  binding  assays  for  1
nd  -AR  are  detailed  in  Supplementary  Material  1.  The
alf-maximal  inhibitory  concentration  (IC50)  values  were
etermined  by  nonlinear,  least-squares  regression  analysis
sing  the  MathIQTM statistical  software  (ID  Business  Solutions
td.,  Surrey,  UK).
Supplementary  Material  1 related  to  this  article  can
e  found,  in  the  online  version,  at  http://dx.doi.org/10.
016/j.psyneuen.2014.09.003.
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2.6.  Experimental  protocols
All  experiments  were  performed  in  16  h-fasted  rats  with  no
access  to  food  post  ICV  injection  except  otherwise  men-
tioned.
2.6.1.  c-Fos  gene  expression  in  rat  brain  induced  by  ICV
UCN
Rats  with  chronic  ICV  cannula  were  injected  ICV  either  with
PBS  or  UCN1  (300  pmol/rat)  and  were  anesthetized  1  h  later
with  sodium  pentobarbital  (50  mg/kg,  IP).  The  brain  was  col-
lected  and  processed  for  c-fos  mRNA  detected  by  in  situ
hybridization  as  detailed  previously  (Yakabi  et  al.,  2011)
(Supplementary  Material  2).  c-Fos  mRNA-positive  cells  in
the  PVN,  VMH,  LC,  NTS,  DMN  and  RVLM  were  unilaterally
counted.
Supplementary  Material  2  related  to  this  article  can
be  found,  in  the  online  version,  at  http://dx.doi.org/10.
1016/j.psyneuen.2014.09.003.
2.6.2.  Effects  of  ICV  UCN1  on  acylated  and  des-acyl
ghrelin  plasma  levels  in  sham  or  vagotomized  rats
Chronically  ICV  cannulated  rats  with  sham  or  subdiaphra-
gmatic  vagotomy  performed  6  days  earlier  were  divided
into  two  groups  (n  =  8—10/group)  and  injected  ICV  with
either  PBS  or  UCN1  (300  pmol/rat).  Rats  were  euthanized
by  decapitation  2  h  after  ICV  injection.  The  trunk  blood  was
collected  for  the  determination  of  acylated  and  des-acyl
ghrelin  levels  in  plasma.  The  ICV  dose  of  UCN1  was  selected,
based  on  our  previous  dose-response  studies  showing  the
maximal  suppression  of  24-h  food  intake  in  rats  and  reduced
fasting  ghrelin  levels  at  1-h  and  2-h  post-ICV  injection
compared  to  ICV  PBS  (Yakabi  et  al.,  2011).
2.6.3.  Effects  of  AR  antagonists,  agonists  or  rikkunshito
on  ICV  UCN1-induced  reduction  of  plasma  acylated
ghrelin  levels
Chronically  ICV-cannulated  rats  were  divided  into  ﬁve
groups  (n  =  8—17/group)  and  injected  ICV  with  PBS  or
UCN1  (300  pmol/rat)  after  the  following  treatments  given
either  IP  15  min  before  or  ICV  simultaneously:  saline,
non-selective  -AR  antagonist  (phentolamine,  5  mg/kg,  IP
or  0.05  mg/rat,  ICV),  selective  1-AR  antagonist  (prazosin,
5  mg/kg,  IP  or  0.50  mg/rat,  ICV),  selective  2-AR  antag-
onist  (yohimbine,  5  mg/kg,  IP  or  0.04  mg/rat,  ICV).  The
regimen  of  AR  blockade  was  based  on  previous  reports
(Becker  et  al.,  1999;  Hosoda  and  Kangawa,  2008).  In
other  sets  of  experiments,  the  IP  pretreatment  were  given
either  15  min  before  or  simultaneously  ICV  UCN1  with  the
following  -AR  antagonists:  non-selective  (propranolol,
3  mg/kg),  1-selective  (atenolol,  10  mg/kg),  or  2-selective
(ICI-118,551,  0.1  mg/kg)  (Hosoda  and  Kangawa,  2008;  Zhao
et  al.,  2010);  the  following  -AR  agonists:  non-selective
(isoproterenol,  0.1  mg/kg),  1-selective  (denopamine,
0.1  mg/kg)  or  2-selective  (salbutamol,  0.1  mg/kg);  or
the  following  -AR  agonists:  non-selective  (synephrine,
5  mg/kg),  1-selective  (phenylephrine,  5  mg/kg),  or  2-
selective  (clonidine,  5  mg/kg)  (Hosoda  and  Kangawa,  2008).
In  the  last  set  of  study,  the  following  pretreatments  were
given  1  h  before  ICV  UCN1:  orogastric  gavage  with  distilled
water  (10  mL/kg)  or  rikkunshito  (0.5  g/kg  or  1.0  g/kg).
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his  regimen  of  administration  was  based  on  our  previous
tudies  (Takeda  et  al.,  2008;  Yakabi  et  al.,  2011).  In  all
xperiments,  the  trunk  blood  was  collected  2  h  after  the
CV  injection  to  determine  the  acylated  ghrelin  levels.
.6.4.  Effects  of  a  selective  2-AR  antagonist  on  ICV
CN1-induced  reduction  of  food  intake
hronically  ICV-cannulated  rats  were  pretreated  IP  with  a
elective  2-AR  antagonist  (yohimbine,  5  mg/kg)  or  vehicle
nd  15  min  later  injected  ICV  with  UCN1  (300  pmol/rat).  To
ssess  the  effects  of  the  ghrelin  antagonist  on  the  selec-
ive  2-AR  antagonist  activities,  rats  were  ﬁrst  injected  IP
ith  saline  or  the  selective  2-AR  antagonist,  and  15  min
ater,  rats  received  an  IV  injection  of  either  saline  or  [D-
ys3]-GHRP-6  (3.7  mg/kg)  followed  1  min  later  by  ICV  PBS  or
CN1  (300  pmol/rat).  Preweighed  chow  was  placed  in  each
age,  and  the  2-h  cumulative  food  intake  was  monitored
mmediately  after  ICV  injection.
.7.  Statistical  analysis
ll  values  are  presented  as  the  mean  ±  standard  error  of  the
ean.  Statistical  analyses  of  the  mean  values  of  two  groups
ere  performed  using  Student’s  t-test  or  the  Aspin-Welch  t-
est.  The  mean  values  of  multiple  groups  were  determined
y  two-way  factorial  analysis  of  variance  (ANOVA)  followed
y  the  Bonferroni  post  hoc  test  or  one-way  analysis  of  vari-
nce  (ANOVA)  followed  by  Dunnett’s  test  or  Steel’s  test.  For
ll  tests,  probability  (P)  values  of  <0.05  were  considered
tatistically  signiﬁcant.
.  Results
.1.  ICV  UCN1  injection  induces  c-fos  mRNA
xpression  in speciﬁc  brain  nuclei
CV  UCN1  (300  pmol/rat)  did  not  inﬂuence  c-fos  mRNA
xpression  in  the  DMN  while  increasing  the  number  of
abeled  cells  in  the  PVN,  VMH,  LC,  NTS  and  RVLM  by  16-,  29-,
-,  37-  and  13-fold,  respectively,  compared  with  ICV  vehicle-
njected  rats  as  monitored  1  h  after  the  peptide  injection  by
n  situ  hybridization  (Supplementary  Fig.  S1  and  Table  S1).
Supplementary  Table  S1  and  Fig.  S1  related  to  this  article
an  be  found,  in  the  online  version,  at  http://dx.doi.org/10.
016/j.psyneuen.2014.09.003.
.2.  Vagotomy  did  not  inﬂuence  ICV  UCN1-induced
eduction  of  plasma  acylated  and  des-acyl  ghrelin
evels
n  the  sham-operated,  fasted  rats,  UCN1  (300  pmol/rat,  ICV)
educed  the  plasma  levels  of  acylated  and  des-acyl  ghrelin
y  31%  and  25%,  respectively,  compared  to  ICV  vehicle
njection  as  monitored  at  2  h  after  the  injection  (Fig.  1A
nd  B).  Similarly,  in  the  rats  with  subdiaphragmatic  vago-
omy,  ICV  UCN1  signiﬁcantly  decreased  plasma  acylated  and
es-acyl  ghrelin  levels  by  41%  (P  <  0.05)  and  33%  (P  <  0.05),
espectively  (Fig.  1A  and  B,  n  =  8—10).  The  magnitude  of
he  reduction  did  not  signiﬁcantly  differ  between  the  sham
nd  vagotomized  groups.  It  is  to  note  that  the  vagotomized
ats  injected  ICV  with  vehicle  showed  a  trend  to  have  an
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Figure  1  Effects  of  vagotomy  on  ICV  UCN1-induced  decrease  in  plasma  levels  of  (A)  acylated  and  (B)  des-acyl  ghrelin  in  rats.  Sub-
diaphragmatic  vagotomy  with  pyloroplasty  or  sham  operation  was  performed  6  days  before  the  experiments.  Rats  were  euthanized
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I h  after  ICV  vehicle  (PBS)  or  UCN1  (300  pmol/rat)  administration
ean ±  standard  error  of  the  mean  (SEM)  (n  =  8—10/group).  Sign
wo-way analysis  of  variance  (ANOVA).  *P  <  0.05  vs.  vagotomy  +  
ncrease  in  acylated  ghrelin  (21%)  and  des-acyl  ghrelin  (22%),
hich  did  not  reach  signiﬁcance  by  using  the  two-way  facto-
ial  analysis  of  variance  (ANOVA)  followed  by  the  Bonferroni
ost  hoc  test  (Fig.  1A  and  1B).  As  acylated  ghrelin  is  the
ctive  form  of  the  peptide  that  activates  GHS-R1a  to  stim-
late  food  intake  (Stengel  et  al.,  2010b),  in  all  subsequent
xperiments,  we  limited  the  plasma  determination  to  the
cylated  form  of  ghrelin.
.3.  Effects  of  IP  injection  or  ICV  injection  of  AR
ntagonists, agonists  or  rikkunshito  on  ICV
CN1-induced  decreases  in  plasma  acylated  ghrelin
n  IP  vehicle-pretreated,  fasted  rats,  ICV  UCN1
300  pmol/rat,  n  =  38)  induced  a  signiﬁcant,  50—59%  reduc-
ion  of  fasted  plasma  levels  of  acylated  ghrelin  compared
ith  ICV  vehicle  (Fig.  2A—D,  P  <  0.001,  P  <  0.01,  P  <  0.01
nd  P  <  0.05,  respectively  [n  =  8—14]).  IP  pretreatment
ith  the  non-selective  -AR  antagonist  (phentolamine)
n
a
f
sd  blood  samples  were  collected.  All  values  are  presented  as  the
nce  was  identiﬁed  using  the  Bonferroni  post  hoc  test  following
reated  group.
r  selective  2-AR  antagonist  (yohimbine)  before  ICV
CN1  increased  signiﬁcantly  and  similarly  plasma  levels
f  acylated  ghrelin  compared  with  those  of  the  vehicle
retreated-plus-ICV  UCN1  group  (58.5  ±  2.5  fmol/mL,
8.6  ±  4.5  fmol/mL  vs.  43.5  ±  4.5  fmol/mL  respectively,
 <  0.05),  while  the  selective  1-AR  antagonist  (prazosin)
ad  no  effect  (44.9  ±  3.6  fmol/mL;  Fig.  2A).  However,  in
he  phentolamine-  or  yohimbine-pretreated  rats,  the  values
emained  signiﬁcantly  lower  than  those  of  the  control
roup  (IP  saline  +  ICV  PBS:  85.5  ±  6.7  fmol/mL,  Dunnett’s
est:  P  <  0.05;  Fig.  2A,  n  =  14—17/group).  Conversely,  the
P  injection  of  the  selective  2-AR  agonist  (clonidine,
 <  0.01),  unlike  a  non-selective  -AR  agonist  (synephrine)
r  a  selective  1-AR  agonist  (phenylephrine),  further
ecreased  the  plasma  acylated  ghrelin  levels  induced  by
CV  UCN1  (Fig.  2B,  n  =  8/group  and  Supplementary  Fig.  S2, =  8/group).  In  a  preliminarily  study,  the  selective  2-AR
ntagonist  did  not  inﬂuence  the  acylated  ghrelin  levels  in
asted  rats.  Furthermore,  a  previous  report  has  shown  no
igniﬁcant  changes  in  the  fasting  levels  of  ghrelin  induced
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cInﬂuence  of  peripheral  2-1 adrenergic  interactions  in  rats
by  the  non-selective  -AR  antagonist  phentolamine  (Hosoda
and  Kangawa,  2008).
Supplementary  Fig.  S2  related  to  this  article  can  be
found,  in  the  online  version,  at  http://dx.doi.org/10.
1016/j.psyneuen.2014.09.003.
With  regard  to  the  inﬂuences  of  -ARs,  we  found
that  the  selective  1-AR  antagonist  (atenolol,  P  <  0.05),
but  not  the  non-selective  -AR  antagonist  (propranolol)
or  the  selective  2-AR  antagonist  (ICI-118,551),  further
decreased  the  plasma  acylated  ghrelin  levels  induced
by  ICV  UCN1  (Fig.  2C,  n  =  8/group).  Conversely,  the
non-selective  -AR  agonist  (isoproterenol,  P  <  0.01)  or  the
selective  1-AR  agonist  (denopamine,  P  <  0.01),  but  not
the  selective  2-AR  agonist  (salbutamol),  prevented  the
decreased  plasma  acylated  ghrelin  levels  elicited  by  ICV
UCN1,  leading  to  acylated  ghrelin  values  not  signiﬁcantly
different  from  those  of  ICV  saline-treated  rats  (Fig.  2D,
n  =  8/group).
When  injected  ICV,  the  non-selective  -AR  antagonist
(phentolamine),  the  selective  1-AR  antagonist  (prazosin)
and  the  selective  2-AR  antagonist  (yohimbine)  did  not  inﬂu-
ence  the  reduction  of  plasma  acylated  ghrelin  levels  induced
by  ICV  UCN1  (Fig.  3A,  n  =  8/group).  Lastly,  the  oral  admin-
istration  of  rikkunshito  signiﬁcantly  inhibited  (P  <  0.05)  the
decreased  plasma  acylated  ghrelin  levels  when  given  at
1  g/kg,  while  at  a  dose  of  0.5  g/kg,  it  had  no  effect  (Fig.  3B,
n  =  14—16/group).
T
d
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Figure  2  Effects  of  IP  pretreatment  with  (A)  -AR  antagonists  (n  =
onists (n  =  8/group),  and  (D)  -AR  agonists  (n  =  8/group)  on  plasma  ac
was performed  15  min  before  ICV  UCN1  (300  pmol/rat)  or  vehicle,  a
presented as  the  mean  ±  SEM.  Signiﬁcance  was  determined  using  Stu
test: *P  <  0.05  and  **P  <  0.01  vs.  UCN1/saline-treated  group.305
.4.  Effects  of  selective  2-antagonist  (yohimbine)
n combination  with  [D-Lys3]-GHRP-6  on  decreased
ood intake  induced  by  ICV  UCN1
n  the  control-pretreated  rats,  ICV  UCN1  induced  a  sig-
iﬁcant  87%  reduction  of  the  cumulative  2-h  food  intake
esponse  to  overnight  fasting  (control:  IP  saline,  IV  saline,
CV  PBS:  4.9  ±  0.4  g/2  h;  IP  saline,  IV  saline,  ICV  UCN1:
.7  ±  0.3  g/2  h,  P  <  0.001;  Fig.  4, n =  7—8/group).  IP  pre-
reatment  with  the  selective  2-AR  antagonist  (yohimbine)
revented  ICV  UCN1  inhibitory  effects  (IP  yohimbine,  IV
aline,  ICV  UCN1:  3.6  ±  1.0  g/2  h,  P  <  0.05)  while  not  inﬂu-
ncing  signiﬁcantly  the  feeding  response  to  the  fast  (IP
ohimbine,  IV  saline,  ICV  PBS:  6.8  ±  1.0  g/2  h  vs.  IP  saline,
V  saline,  ICV  PBS:  6.4  ±  0.7  g/2  h).  [D-Lys3]-GHRP-6  injected
V  did  not  inﬂuence  the  2-h  cumulative  food  intake  in
ehicle-treated  control  rats  while  completely  blocking  the
ormalization  of  feeding  induced  by  IP  yohimbine  in  ICV
CN1-treated  rats  (Fig.  4,  n  =  7—8/group).
.5.  In  vitro  binding  assays  of  rikkunshito
omponents  on  ARshe  AR  binding-inhibitory  activities  (IC50)  of  the  crude
rug  components  contained  in  rikkunshito  were  tested  in
ransfected  cells  with  human  AR  subtypes.  As  shown  in
 14—17/group),  (B)  -AR  agonists  (n  =  8/group),  (C)  -AR  antag-
ylated  ghrelin  levels  inhibited  by  ICV  UCN1  in  rats.  IP  injection
nd  trunk  blood  samples  were  collected  2  h  later.  All  values  are
dent’s  t-test  or  one-way  ANOVA  followed  by  post  hoc  Dunnett’s
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Figure  3  Effects  of  ICV  with  (A)  selective  -AR  antagonists  (n  =  8/group)  and  (B)  orogastric  administration  of  rikkunshito
(n =  14—16/group)  on  acylated  ghrelin  levels  inhibited  by  ICV  UCN1  in  rats.  ICV  was  performed  simultaneously  with  UCN1
(300 pmol/rat)  or  vehicle.  Distilled  water  or  rikkunshito  was  orogastrically  administered  (10  mL/kg)  1  h  before  ICV  injection  of
PBS or  UCN1  (300  pmol/rat),  the  rats  were  euthanized  2  h  later,  and  blood  samples  were  collected.  All  values  are  presented  as
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ahe mean  ±  SEM.  Signiﬁcance  was  determined  using  Student’s  
CN1 +  Distilled  water-treated  group.
able  1,  glycycoumarin  6-,  8-shogaol  and  10-gingerol,  and
udesmol  display  inhibitory  activity  to  2A-AR  and  differ-
ntial  activities  on  1-AR  or  1,3-AR  (Supplementary  Table
2).
Supplementary  Table  S2  related  to  this  article  can
e  found,  in  the  online  version,  at  http://dx.doi.org/10.
016/j.psyneuen.2014.09.003.
. Discussion
e  found  that  ICV  UCN1-induced  reduction  of  plasma  ghrelin
evels  was  not  altered  by  vagotomy  and  attenuated  by  the
eripheral  blockade  of  2-AR  and  restored  by  the  activa-
ion  of  1-AR  in  rats.  Conversely,  2-AR  agonist  and  1-AR
ntagonist  enhanced  the  inhibitory  effect  of  ICV  UCN1.  This
2-AR-ghrelin  inhibitory  pathway  has  functional  relevance
ince  yohimbine  prevented  the  anorexic  effect  of  ICV  UCN1
g
e
v
(t  or  ANOVA  followed  by  post  hoc  Dunnett’s  tests:  *P  <  0.05  vs.
nd  the  2-AR  action  was  abolished  by  the  ghrelin  receptor
ntagonist.
UCN1  injected  ICV  at  300  pmol/rat  reproducibly
ecreased  by  50—59%  plasma  levels  of  acylated  ghrelin  in
asted  rats  consistent  with  our  previous  report  (Saegusa
t  al.,  2011;  Yakabi  et  al.,  2011).  UCN1  action  is  brain-
ediated  and  does  not  reﬂect  peptide  leakage  into  the
eriphery  since  systemic  injection  of  UCN1  increases  the
otal  ghrelin  plasma  levels  in  fed  rats  or  had  no  effect
n  fasted  state  (Wang  et  al.,  2006,  2013).  It  has  been
ell  established  that  the  majority  of  circulating  ghrelin  is
roduced  by  X/A-like  cells  located  in  the  gastric  mucosa,
s  indicated  by  the  pronounced  reduction  of  circulating
hrelin  after  gastrectomy  (Ariyasu  et  al.,  2001;  Mizutani
t  al.,  2009).  The  stomach  receive  prominent  vagal  inner-
ation  through  efferent  projections  from  DMN  neurons
Berthoud  et  al.,  1991).  Central  vagal  activation  (Stengel
Inﬂuence  of  peripheral  2-1 adrenergic  interactions  in  rats  
Figure  4  Effects  of  selective  2-AR  antagonist  (yohimbine)
alone  or  in  combination  with  a  ghrelin  receptor  antagonist
on food  intake  in  ICV  UCN1-treated  rats.  Saline  or  yohim-
bine (5  mg/kg)  was  administrated  intraperitoneally  15  min
before  ICV  injection  of  PBS  or  UCN1  (300  pmol/rat).  Saline  or
[D-Lys3]-GHRP-6  (3.7  mg/kg)  was  administrated  intravenously
into the  tail  vein  1  min  after  ICV  administration  of  PBS  or
UCN1 (300  pmol/rat).  Each  bar  represents  the  mean  ±  SEM
(n =  7—8/group).  Signiﬁcance  was  determined  using  Steel’s  post
hoc test  following  one-way  ANOVA  analysis  *P  <  0.05  compared
with the  UCN1/saline  group.  Signiﬁcance  was  determined  using
Aspin—welch  t-test.  +P  <  0.05  vs.  the  UCN1/selective  2-AR
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bine,  partially  prevented  ICV  UCN1-induced  reduction  ofantagonist  (yohimbine)  group.  Signiﬁcance  between  PBS  and
UCN1/saline  was  determined  using  Student’s  t-test.
et  al.,  2010a)  and  peripheral  acetylcholine  administration
(Shrestha  et  al.,  2009)  reportedly  increase  ghrelin  release,
while  muscarinic  receptor  antagonists  suppress  ghrelin
secretion  in  fasted  rats  (Hosoda  and  Kangawa,  2008).
However,  ICV  UCN1  action  is  unlikely  to  be  mediated  by
alterations  of  vagal  pathway  as  reported  for  the  inhibitory
inﬂuence  of  intracisternally  injected  UCN1  on  gastric
emptying  in  rats  (Czimmer  et  al.,  2006).  This  is  supported
by  the  observation  that  subdiaphragmatic  vagotomy  did
not  alter  the  magnitude  of  ghrelin  decrease  induced  by  ICV
p
w
a
Table  1  Binding  assays  for  2-adrenergic  receptors  by  rikkunshit
Rikkunshito  components
Glysyrrhizae  Radix  Glycycoumarin  
Zingiberis
Rhizoma
6-Shogaol 
8-Shogaol  
10-Gingerol  
Aurantii Nobilis
pericarpium
Heptamethoxyﬂavone  
Synephrine  
Atractylodis Lanceae  Rhizoma Eudesmol  
(—): Indicates more than 100 mol/L as IC50 values.
NS: Non selective.
Each value indicates the mean ± SEM of three samples as mol/L.307
CN1.  Moreover  c-fos  mRNA,  which  is  used  as  a  marker
f  autonomic  neuronal  activation  (Krukoff,  1993),  was  not
nduced  in  DMN  neurons  by  ICV  UCN1  (Supplementary  Fig.
1  and  Table  S1)  as  previously  observed  (Yakabi  et  al.,
011).
In  contrast,  there  are  compelling  reports  documenting
hat  ICV  injection  of  UCN1  activates  the  core  group  of
utonomic  brain  structures  regulating  sympathetic  outﬂow,
amely  the  PVN,  LC,  NTS  and  RVLM,  as  monitored  by  the
obust  induction  of  Fos  immunoreactivity  (Bittencourt  et  al.,
999;  Daniels  et  al.,  2004) or  c-fos  gene  expression  including
nder  similar  conditions  associated  with  decreased  ghrelin
lasma  levels  (Yakabi  et  al.,  2011)  and  as  well  as  in  the
resent  study  (Supplementary  Fig.  S1  and  Table  S1).  We  have
reviously  reported  that  ICV  UCN1-induced  decreased  cir-
ulating  levels  of  acylated  ghrelin  are  mediated  by  brain
RF2 (Yakabi  et  al.,  2011).  Other  function  data  support
hat  activation  of  CRF2 in  the  PVN  stimulates  sympathetic
erve  activity  in  rat  the  viscera  (Li  et  al.,  2010).  These  data
rovide  neuroanatomical  and  functional  support  for  a  supra
pinal  sites  of  action  of  ICV  UCN1  to  activate  sympathetic
utﬂow.  However,  it  cannot  be  ruled  out  that  an  additional
horacic  site  regulating  sympathetic  nerve  (Quinson  et  al.,
001) can  also  be  involved  in  ICV  UCN1  action.
Activation  of  sympathetic  pathways  release  nore-
inephrine  from  nerve  endings  that  bind  to  ARs,  which
re  classiﬁed  into  - and  -ARs  based  on  their  responses
o  various  catecholamines.  Previous  studies  in  rats  have
ndicated  that  fasting  plasma  levels  of  ghrelin  are  stimu-
ated  by  -AR  antagonists  and  -AR  agonists  and  inhibited
y  -AR  agonists  (Hosoda  and  Kangawa,  2008).  In  the
resent  study,  a  pharmacologic  approach  using  peripheral
dministered  selective  - and  -AR  subtype  antagonists  and
gonists  revealed  that  2-AR  antagonist  and  1-AR  agonist
aise,  while  2-AR  agonist  and  1-AR  antagonist  further
uppress,  the  lowered  ghrelin  plasma  levels  under  condi-
ions  of  ICV  UCN1  injection  in  fasted  rats.  In  support  of  this
ssertion,  the  peripheral  injection  of  the  -AR  antagonist,
hentolamine,  and  the  selective  2-AR  antagonist,  yohim-lasma  acylated  ghrelin.  Conversely,  the  activation  of  2-AR
ith  IP  injection  of  clonidine  exerted  inhibitory  effects,
s  shown  by  the  dose-related  further  decreased  of  ghrelin
o  components  (IC50 values).
2-adrenergic  receptor  subtypes
A  B  C  NS
5.2  ±  0.7  39.4  ±  3.3  14.5  ±  0.3  —
24.7  ±  2.4  —  —  —
5.7  ±  0.8  —  6.1  ±  0.5  —
5.4  ±  0.2  30.9  ±  1.9  6.6  ±  0.8  —
—  —  —  —
—  —  —  11.2  ±  1.2
37.2  ±  4.4  —  —  —
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lasma  levels  in  ICV  UCN1-treated  rats  (Supplementary
ig.  S2).  Although  peripherally  administered  the  selective
2-AR  antagonist  yohimbine  crosses  the  blood-brain  barrier
Szemeredi  et  al.,  1991),  however  it  is  likely  that  yohimbine
xerts  its  action  peripherally,  because,  when  administered
CV,  this  2-AR  antagonist  did  not  inﬂuence  the  decreased
hrelin  levels  in  response  to  ICV  UCN1.
Additional  pharmacological  studies  established  the  speci-
city  toward  peripheral  2-ARs  since  under  the  same
onditions,  the  1-AR  antagonist  (prazosin)  or  -AR  antago-
ists  (propanolol  or  the  2-AR  antagonist,  ICI-118,551)  had
ither  no  effect  or  further  (the  1-AR  antagonist,  atenolol)
nhanced  the  inhibitory  effects  of  ICV  UCN1.  Likewise,  the
ctivation  of  other  -  or  -AR  subtypes  by  agonists  could
ot  mimic  the  inhibitory  effects  of  UCN1,  as  shown  by  the
ack  of  effect  of  IP  injection  of  -AR  agonist,  synephrine,
he  1-AR  agonist,  phenylephrine,  or  the  2-AR  agonist,
albutamol.  In  addition,  we  showed  that  the  IP  injection  of
on-selective  -AR  agonist,  isoproterenol  or  the  selective
1-AR  agonist,  denopamine,  restored  the  basal  plasma  lev-
ls  of  acylated  ghrelin  in  ICV  UCN1-injected  rats.  This  may
epresent  a  direct  action  on  X/A  like  cells.  This  ﬁnding  is
upported  by  a  recent  study  using  a  culture  ghrelinoma  cells
ine  showing  that  ghrelin  release  is  also  stimulated  selec-
ively  by  the  activation  of  1-AR  agonist  and  inhibited  by
1-AR  antagonist,  atenonol  (Zhao  et  al.,  2010).  Other  in  vivo
tudies  have  shown  that  noradrenalin  raises  the  ghrelin  lev-
ls  measured  in  efﬂuent  of  microdialysis  probe  implanted
nto  the  rat  gastric  submucosa  (de  la  Cour  et  al.,  2007).
dditionally,  electrically  stimulated  postganglionic  sympa-
hetic  axons  projecting  from  the  celiac  ganglions  of  rats
ncreases  ghrelin  release  (Mundinger  et  al.,  2006).  Taken
ogether,  it  may  be  speculated  that  the  2-AR  antagonist,
ohimbine-induced  partial  reversal  of  decreased  levels  of
hrelin  under  conditions  of  sympathetic  activation  by  ICV
CN1  may  reﬂect  the  balance  between  the  inhibitory  and
timulatory  action  of  peripheral  2-AR  and  1-AR  activation,
espectively.  However,  the  cellular  mechanisms  by  which
he  peripheral  2-ARs  contribute  to  reduce  the  decline  of
hrelin  plasma  levels  in  ICV  UCN1-treated  rats  will  require
urther  investigation.  The  2-AR  genes  were  expressed  in
he  rat  stomach  under  our  conditions  (Supplementary  Fig.
3)  were  consistent  with  a  previous  study  showing  2A-AR,
2B-AR  and  2c-AR  mRNA  levels  in  the  gastric  mucosa  of  rats
ith  a  more  abundant  expression  of  the  message  for  2A-AR
Gyires  et  al.,  2007).  This  suggests  that  2-ARs  may  directly
r  indirectly  regulate  gastric  ghrelin  secretion.
Supplementary  Fig.  S3  related  to  this  article  can  be
ound,  in  the  online  version,  at  http://dx.doi.org/10.
016/j.psyneuen.2014.09.003.
Irrespective  of  the  mechanisms  involved,  we  showed  that
he  2-AR  signaling  pathway  has  functional  relevance  to
hlerin  secretion.  ICV  UCN1  decreased  the  feeding  response
o  an  overnight  fast  consistent  with  previous  reports  (Benoit
t  al.,  2000;  Smagin  et  al.,  1998;  Spina  et  al.,  1996;  Yakabi
t  al.,  2011).  This  was  prevented  by  the  2-AR  antagonist,
ohimbine.  In  addition,  the  simultaneous  administration  of
 ghrelin  receptor  antagonist  and  2-AR  antagonist  com-
letely  abolished  the  effects  achieved  by  2-AR  antagonist
dministration  alone.  Likewise,  rikkunshito  established  as
n  enhancer  of  endogenous  ghrelin  secretion  (Takeda  et  al.,
012)  administered  orogastrically  also  increased  plasma
T
S
C
(K.  Yakabi  et  al.
cylated  ghrelin  inhibited  by  ICV  UCN1.  This  was  associ-
ted  with  the  suppression  of  the  reductions  in  food  intake
Supplementary  Fig.  S4)  was  consistent  with  our  previ-
us  data  (Yakabi  et  al.,  2011).  We  reported  recently  that
he  decreased  food  intake  following  ICV  UCN1  injection
as  improved  by  the  administration  of  exogenous  acylated
hrelin  (Yakabi  et  al.,  2011).  Collectively,  these  ﬁndings
oint  to  a  role  of  ghrelin  receptor  activation  to  restore
eeding  behavior  under  conditions  of  decreased  circulating
hrelin  induced  by  ICV  UCN1.
Supplementary  Fig.  S4  related  to  this  article  can  be
ound,  in  the  online  version,  at  http://dx.doi.org/10.
016/j.psyneuen.2014.09.003.
Lastly,  in  order  to  validate  further  our  hypothesis  that  the
CN1-induced  reduction  in  food  intake  involved  the  activa-
ion  of  peripheral  2-ARs,  we  assessed  whether  rikkunshito
unctions  as  a  2-AR  antagonist.  Rikkunshito  is  a  mixture
f  herbal  ingredients;  therefore,  in  this  study,  we  exam-
ned  its  34  components  using  an  in  vitro  AR  binding  assay.
e  found  that  several  components,  namely  glycycoumarin,
-  and  8-shogaol,  10-gingerol  and  eudesmol,  functioned  as
2-AR  antagonists.  These  results  suggest  that  the  effects
f  rikkunshito  on  decreased  food  intake  in  response  to  ICV
CN1  administration  may  be  induced  through  the  2-AR
ntagonist  property  of  some  of  its  speciﬁc  components.
In  conclusion,  the  present  ﬁndings  indicate  that  ICV
CN1-induced  reduction  of  fasting  plasma  levels  of  acylated
hrelin  is  independent  from  the  vagus  nerve,  while  it  is  asso-
iated  with  the  activation  of  speciﬁc  brain  nuclei  inﬂuencing
ympathetic  pathways.  The  peripheral  AR  effectors  mediat-
ng  ghrelin  decline  after  ICV  UCN1  involve  the  activation  of
2-ARs  and  the  dampening  of  1-AR  stimulatory  effect  on
hrelin  release.  The  2-ARs  activation  and  related  ghrelin
ecline  contribute  to  the  inhibition  of  feeding  response  to
 fast  induced  by  ICV  UCN1.  It  suggests  that  2-AR  antag-
nists  may  improve  alterations  of  food  intake  linked  with
uppression  of  ghrelin  under  conditions  of  brain  CRF  receptor
ctivation.
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